-- Valeant says can't justify matching Actavis bid for Allergan
-- By Rod Nickel in Winnipeg
-- Mon Nov 17, 2014 09:40AM EST
-- None



Nov 17 (Reuters) - Valeant Pharmaceuticals International Inc <VRX.TO> Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's <ACT.N> $219 per share bid for Allergan Inc <AGN.N>.

